Hook
The Supreme Court issued an emergency order this week keeping mifepristone available by telehealth while litigation continues. The case has nothing to do with whether the drug works or whether abortion is legal. It turns on a narrower question: when regulators approve a medical treatment based on evidence, who gets to challenge that approval in court?
The answer reveals how regulatory systems separate scientific questions from procedural ones—and why courts enforce that separation.
What Fda Approval Means
FDA drug approval works in three phases. Phase I tests safety in small groups. Phase II tests efficacy and dosing. Phase III runs large controlled trials comparing the drug to placebo or standard care. The FDA reviews all three, plus manufacturing data, and asks: does the evidence show benefit outweighs risk under specific conditions?
Approval doesn’t mean “perfectly safe.” It means “the data support use in defined populations with known risks.” Mifepristone’s FDA approval in 2000 included conditions: use up to seven weeks gestation, three in-person visits, signed patient agreement form. Over 20 years, post-market data showed complications were rare—serious adverse events under 1%. The FDA updated the protocol in 2016 and 2021: extended to 10 weeks, reduced to one in-person visit, then allowed telehealth prescribing.
Each change followed the same process: new evidence, risk-benefit recalculation, regulatory update. This is how science-based regulation works—conditions evolve as data accumulate.
Standing Doctrine
To sue over a federal regulation, you must show standing: concrete harm to you, not abstract disagreement with the policy. The medical groups challenging mifepristone argued the drug harmed their practices because they occasionally treated patients with complications. The Supreme Court said that’s not standing. Treating complications from a legal drug someone else prescribed doesn’t make you injured by the drug’s approval—it makes you a doctor doing your job.
Standing is a gatekeeper rule. It prevents every policy dispute from becoming a lawsuit. If disapproval were enough, any regulation could be challenged by anyone who objects. Courts require injury specific to the plaintiff: lost income, restricted rights, concrete harm. “I don’t like how this policy affects other people” doesn’t clear the bar.
The Court didn’t rule on mifepristone’s safety. It ruled the challengers hadn’t shown they were hurt by its availability.
Regulatory Deference
When courts review agency decisions on scientific questions, they generally defer to the agency’s expertise. The standard: did the agency follow proper process and base its decision on valid evidence? Courts don’t re-run clinical trials. They ask whether the FDA used the data it had, applied consistent evidentiary standards, and documented its reasoning.
This is regulatory deference. The FDA employs pharmacologists, statisticians, clinicians. Courts employ judges and clerks. When the question is “does this adverse-event rate justify restricting access,” the agency’s scientific judgment gets deference unless the process was broken or the evidence was ignored.
Deference has limits—if an agency acts beyond its statutory authority or ignores its own rules, courts intervene. But on questions within the agency’s wheelhouse, the threshold is process and evidence, not whether the judge would have decided differently.
The mifepristone ruling didn’t second-guess the FDA’s risk assessment. It reinforced that regulatory decisions on medical evidence belong to regulators, not litigants who disagree with the outcome.
Telehealth Layer
Telehealth regulation doesn’t govern the drug—it governs the delivery model. The question: can a prescriber evaluate risk and obtain informed consent without in-person examination? For mifepristone, the FDA reviewed studies comparing telehealth and in-person prescribing. The data showed no significant difference in adverse events, patient comprehension, or follow-up compliance.
That evidence supported removing the in-person visit requirement. The safety profile didn’t change; the FDA determined that the safeguards (patient screening, dosing protocols, access to emergency care) worked equally well when administered remotely.
This is standard regulatory updating. When new delivery models emerge—mail-order pharmacy, telemedicine, at-home diagnostic tests—regulators assess whether existing restrictions still serve their purpose. If the risk stays controlled under the new model, restrictions that only made sense for in-person care get revised.
Telehealth mifepristone access wasn’t invented by judicial ruling. It was a regulatory decision grounded in post-market surveillance and comparative outcome data, reviewed by courts only for procedural soundness.
Close
Regulatory systems separate “does this work?” from “do I like this?” Courts enforce that separation by requiring standing—you can’t sue just because you disapprove of someone else’s care. The mifepristone ruling held that line. Science questions go to scientists. Standing questions go to courts. Policy disagreements that don’t produce concrete personal harm don’t become lawsuits.